Rheumatoid Arthritis Completed Phase 1 Trials for Sarilumab (DB11767)

Also known as: Rheumatoid Arthritis(RA) / Rheumatoid Arthritis, NOS / Rheumatoid Arthritis RA / Rhematoid Arthritis / Rheumatic Arthritis / Rheumatoid Arthritis (RA) / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Arthritis, Rheumatoid (RA) / Rheumatoid Arthritis(RA) / RA / Systemic rheumatoid arthritis / Rheumatoid arthritis (disorder) / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Rheumatoid arthritis NOS / Rheumatoid arthritis NOS (disorder)

DBCOND0027961 (Rheumatoid Arthritis)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01328522Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis PatientsTreatment
NCT02404558Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid ArthritisTreatment
NCT02097524Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)Basic Science
NCT02017639Sarilumab Effect on the Pharmacokinetics of SimvastatinHealth Services Research
NCT01850680Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid ArthritisTreatment
NCT01011959A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis SubjectsTreatment
NCT01055899Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid ArthritisTreatment
NCT01026519A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid ArthritisTreatment